Neumora Therapeutics, Inc.
NMRA
$1.28
-$0.12-8.57%
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 17.01M | 16.02M | 15.19M | 14.32M | 11.24M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 62.92M | 76.65M | 63.82M | 60.07M | 50.10M |
Operating Income | -62.92M | -76.65M | -63.82M | -60.07M | -50.10M |
Income Before Tax | -58.82M | -72.49M | -58.58M | -53.72M | -108.46M |
Income Tax Expenses | 0.00 | 53.00K | 125.00K | -- | 268.00K |
Earnings from Continuing Operations | -58.82M | -72.55M | -58.70M | -53.72M | -108.73M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -58.82M | -72.55M | -58.70M | -53.72M | -108.73M |
EBIT | -62.92M | -76.65M | -63.82M | -60.07M | -50.10M |
EBITDA | -62.77M | -76.49M | -63.66M | -59.92M | -49.93M |
EPS Basic | -0.37 | -0.45 | -0.37 | -0.34 | -0.71 |
Normalized Basic EPS | -0.23 | -0.28 | -0.23 | -0.21 | -0.18 |
EPS Diluted | -0.37 | -0.45 | -0.37 | -0.34 | -0.71 |
Normalized Diluted EPS | -0.23 | -0.28 | -0.23 | -0.21 | -0.18 |
Average Basic Shares Outstanding | 160.98M | 159.58M | 158.98M | 157.94M | 152.83M |
Average Diluted Shares Outstanding | 160.98M | 159.58M | 158.98M | 157.94M | 152.83M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |